COVID-19 HSE Weekly Booster Vaccination Figures

Category: Health
Views: 30
Openness rating:

Please see FAQ for latest information on COVID-19 Data Hub Data Flows   https://covid-19.geohive.ie/pages/helpfaqs Category Field Label Field Display Name Explanation

ExtractDate ExtractDate Date the data is extracted

Latitude Latitude

Longitude Longitude

EpiWeek EpiWeek Details of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/

Week Week Details of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/

WeeklyBoosterVaccines Weekly Booster Vaccines Amount of boosters given during week

Vaccine Brand AstraZeneca AstraZeneca

Janssen Janssen

Moderna Moderna

Pfizer Pfizer

Additional Doses by Brand AD_AstraZeneca AdditionalDoses AstraZeneca

AD_Janssen AdditionalDoses Janssen

AD_Moderna AdditionalDoses Moderna

AD_Pfizer AdditionalDoses Pfizer

Immunocompromised Doses by Brand ID_AstraZeneca ImmunocompromisedDoses AstraZeneca

ID_Janssen ImmunocompromisedDoses Janssen

ID_Moderna ImmunocompromisedDoses Moderna

ID_Pfizer ImmunocompromisedDoses Pfizer

Gender Male Male

Female Female

Not Assigned NA

Age Group Additional Dose AD_Age0to9 AdditionalDose Age5to11 Additional Dose Age 5 to 11

AD_Age10to19 AdditionalDose Age12to19 Additional Dose Age 12 to 19

AD_Age20to29 AdditionalDose Age20to29 Additional Dose Age 20 to 29

AD_Age30to39 AdditionalDose Age30to39 Additional Dose Age 30 to 39

AD_Age40to49 AdditionalDose Age40to49 Additional Dose Age 40 to 49

AD_Age50to59 AdditionalDose Age50to59 Additional Dose Age 50 to 59

AD_Age60to69 AdditionalDose Age60to69 Additional Dose Age 60 to 69

AD_Age70to79 AdditionalDose Age70to79 Additional Dose Age 70 to 79

AD_Age80_ AdditionalDose Age80+ Additional Dose Age 80+

AD_NA AdditionalDose NotAssigned Additional Dose Not Assigned To Age Group

Age Group Additional Dose Cumulative AD_Age0to9_Cum AdditionalDose Cumulative Age5to11 Additional Dose Cumulative Age 5 to 11

AD_Age10to19_Cum AdditionalDose Cumulative Age12to19 Additional Dose Cumulative Age 12 to 19

AD_Age20to29_Cum AdditionalDose Cumulative Age20to29 Additional Dose Cumulative Age 20 to 29

AD_Age30to39_Cum AdditionalDose Cumulative Age30to39 Additional Dose Cumulative Age 30 to 39

AD_Age40to49_Cum AdditionalDose Cumulative Age40to49 Additional Dose Cumulative Age 40 to 49

AD_Age50to59_Cum AdditionalDose Cumulative Age50to59 Additional Dose Cumulative Age 50 to 59

AD_Age60to69_Cum AdditionalDose Cumulative Age60to69 Additional Dose Age 60 to 69

AD_Age70to79_Cum AdditionalDose Cumulative Age70to79 Additional Dose Age 70 to 79

AD_Age80__Cum AdditionalDose Cumulative Age80+ Additional Dose Cumulative Age 80+

AD_NA_Cum AdditionalDose Cumulative Not Assigned Additional Dose Cumulative Not Assigned To Age Group

Age Group Immunocompromised Dose ID_Age0to9 ImmunocompromisedDoses Age5to11 Immunocompromised Dose Age 5 to 11

ID_Age10to19 ImmunocompromisedDoses Age12to19 Immunocompromised Dose Age 12 to 19

ID_Age20to29 ImmunocompromisedDoses Age20to29 Immunocompromised Dose Age 20 to 29

ID_Age30to39 ImmunocompromisedDoses Age30to39 Immunocompromised Dose Age 30 to 39

ID_Age40to49 ImmunocompromisedDoses Age40to49 Immunocompromised Dose Age 40 to 49

ID_Age50to59 ImmunocompromisedDoses Age50to59 Immunocompromised Dose Age 50 to 59

ID_Age60to69 ImmunocompromisedDoses Age60to69 Immunocompromised Dose Age 60 to 69

ID_Age70to79 ImmunocompromisedDoses Age70to79 Immunocompromised Dose Age 70 to 79

ID_Age80_ ImmunocompromisedDoses Age80+ Immunocompromised Dose Age 80+

ID_NA ImmunocompromisedDoses Not Assigned Immunocompromised Dose Not Assigned To Age Group

Age Group Immunocompromised Dose Cumulative ID_Age0to9_Cum ImmunocompromisedDoses Cumulative Age5to11 Immunocompromised Dose Cumulative Age 5 to 11

ID_Age10to19_Cum ImmunocompromisedDoses Cumulative Age12to19 Immunocompromised Dose Cumulative Age 12 to 19

ID_Age20to29_Cum ImmunocompromisedDoses Cumulative Age20to29 Immunocompromised Dose Cumulative Age 20 to 29

ID_Age30to39_Cum ImmunocompromisedDoses Cumulative Age30to39 Immunocompromised Dose Cumulative Age 30 to 39

ID_Age40to49_Cum ImmunocompromisedDoses Cumulative Age40to49 Immunocompromised Dose Cumulative Age 40 to 49

ID_Age50to59_Cum ImmunocompromisedDoses Cumulative Age50to59 Immunocompromised Dose Cumulative Age 50 to 59

ID_Age60to69_Cum ImmunocompromisedDoses Cumulative Age60to69 Immunocompromised Dose Age 60 to 69

ID_Age70to79_Cum ImmunocompromisedDoses Cumulative Age70to79 Immunocompromised Dose Age 70 to 79

ID_Age80__Cum ImmunocompromisedDoses Cumulative Age80+ Immunocompromised Dose Cumulative Age 80+

ID_NA_Cum ImmunocompromisedDoses Cumulative NotAssigned Immunocompromised Dose Cumulative Not Assigned To Age Group

Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Each Age Group BoosterPer_Age0to9 IDandADTotal % of Population Age5to11 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 5 to 11

BoosterPer_Age10to19 IDandADTotal % of Population Age12to19 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 12 to 19

BoosterPer_Age20to29 IDandADTotal % of Population Age20to30 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 20 to 29

BoosterPer_Age30to39 IDandADTotal % of Population Age30to40 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 30 to 39

BoosterPer_Age40to49 IDandADTotal % of Population Age40to50 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 40 to 49

BoosterPer_Age50to59 IDandADTotal % of Population Age50to60 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 50 to 59

BoosterPer_Age60to69 IDandADTotal % of Population Age60to70 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 60 to 69

BoosterPer_Age70to79 IDandADTotal % of Population Age70to80 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 70 to 79

BoosterPer_Age80_ IDandADTotal % of Population Age80+ Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 80+

BoosterPer_NA IDandADTotal % of Population Not Assigned Immunocompromised Dose and Additional Dose Administered As A Percentage of Population Not Assigned To Age Group

  • Go to resource

Resource: Shapefile

URL: https://opendata-geohive.hub.arcgis.com/datasets/2a4814b66d0d459cbb80dea30f61fbfe_0.zip?outSR=%7B%22latestWkid%22%3A3857%2C%22wkid%22%3A102100%7D

There are no views created for this resource yet.

Additional Information

Field Value
Data last updated 19 August 2022
Metadata last updated 19 August 2022
Created 19 August 2022
Format ZIP
License Creative Commons Attribution 4.0
Id7bf43422-bb04-4ffa-8a82-15390e822324
Mimetypeapplication/zip
Package id81c7c0d5-9ae1-4de6-b4e9-c53cdd7f24a6
Position5
Stateactive
Description
High Value Dataset (HVD) Resource
Applicable Legislation
API response formats
    API type
    API access url